Polygenic resilience score may be sensitive to preclinical Alzheimer’s disease changes

Late-onset Alzheimer’s disease (LOAD) is a polygenic disorder with a long prodromal phase, making early diagnosis challenging. Twin studies estimate LOAD as 60–80% heritable, and while common genetic variants can account for 30% of this heritability, nearly 70% remains “missing”. Polygenic risk scores (PRS) leverage combined effects of many loci to predict LOAD risk, but often lack sensitivity to preclinical disease changes, limiting clinical utility. Our group has built and published on a resilience phenotype to model better-than-expected cognition give amyloid pathology burden and hypothesized it may assist in preclinical polygenic risk prediction. Thus, we built a LOAD PRS and a resilience PRS and evaluated both in predicting cognition in a dementia-free cohort (N=254). The LOAD PRS had a significant main effect on baseline memory (β=−0.18, P=1.68E-03). Both the LOAD PRS (β=−0.03, P=1.19E-03) and the resilience PRS (β=0.02, P=0.03) had significant main effects on annual memory decline. The resilience PRS interacted with CSF Aβ on baseline memory (β=−6.04E-04, P=0.02), whereby it predicted baseline memory among Aβ+ individuals (β=0.44, P=0.01) but not among Aβ− individuals (β=0.06, P=0.46). Excluding APOE from PRS resulted in mainly LOAD PRS associations attenuating, but notably the resilience PRS interaction with CSF Aβ and selective prediction among Aβ+ individuals was consistent. Although the resilience PRS is currently somewhat limited in scope from the phenotype’s cross-sectional nature, our results suggest that the resilience PRS may be a promising tool in assisting in preclinical disease risk prediction among dementia-free and Aβ+ individuals, though replication and fine-tuning are needed.

[1]  J. Lambert,et al.  Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults , 2022, Neurology.

[2]  O. Andreassen,et al.  Polygenic resilience scores capture protective genetic effects for Alzheimer’s disease , 2022, Translational Psychiatry.

[3]  Nick C Fox,et al.  New insights into the genetic etiology of Alzheimer’s disease and related dementias , 2022, Nature Genetics.

[4]  N. Pedersen,et al.  Measuring heritable contributions to Alzheimer’s disease: polygenic risk score analysis with twins , 2022, Brain communications.

[5]  W. M. van der Flier,et al.  Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score , 2021, Alzheimer's & dementia.

[6]  J. Faul,et al.  Considering the APOE locus in Alzheimer’s disease polygenic scores in the Health and Retirement Study: a longitudinal panel study , 2020, BMC medical genomics.

[7]  K. Kauppi,et al.  Effects of polygenic risk for Alzheimer’s disease on rate of cognitive decline in normal aging , 2020, Translational Psychiatry.

[8]  P. Vemuri,et al.  Improving the resistance and resilience framework for aging and dementia studies , 2020, Alzheimer's Research & Therapy.

[9]  Timothy J. Hohman,et al.  Genetic variants and functional pathways associated with resilience to Alzheimer’s disease , 2020, bioRxiv.

[10]  Yanjiang Wang,et al.  Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in a Chinese Cohort , 2020, Neuroscience Bulletin.

[11]  M. Pirinen,et al.  A polygenic resilience score moderates the genetic risk for schizophrenia , 2019, Molecular Psychiatry.

[12]  J. Hardy,et al.  Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition , 2019, Annals of neurology.

[13]  J. Hardy,et al.  Alzheimer’s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment , 2019, Translational Psychiatry.

[14]  Brian E. Cade,et al.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program , 2019, Nature.

[15]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[16]  Eden R Martin,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[17]  Dominic Holland,et al.  Polygenic hazard score, amyloid deposition and Alzheimer’s neurodegeneration , 2019, Brain : a journal of neurology.

[18]  O. Andreassen,et al.  Use of an Alzheimer’s disease polygenic risk score to identify mild cognitive impairment in adults in their 50s , 2019, Molecular Psychiatry.

[19]  Y. Stern,et al.  Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance , 2018, Alzheimer's & Dementia.

[20]  R. Sperling,et al.  Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition , 2018, Neurology.

[21]  Timothy J. Hohman,et al.  Subclinical Compromise in Cardiac Strain Relates to Lower Cognitive Performances in Older Adults , 2018, Journal of the American Heart Association.

[22]  O. Andreassen,et al.  Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition , 2017, bioRxiv.

[23]  Lilah M. Besser,et al.  Polygenic hazard scores in preclinical Alzheimer’s disease , 2017, bioRxiv.

[24]  Lilah M. Besser,et al.  Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score , 2017, PLoS medicine.

[25]  Sterling C. Johnson,et al.  Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[26]  Alan M. Kwong,et al.  Next-generation genotype imputation service and methods , 2016, Nature Genetics.

[27]  R. Buckner,et al.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes , 2016, Neurology.

[28]  Timothy J. Hohman,et al.  The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. , 2016, Journal of Alzheimer's disease : JAD.

[29]  K. Blennow,et al.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. , 2015, Brain : a journal of neurology.

[30]  Gonçalo R. Abecasis,et al.  Minimac2: Faster Genotype Imputation , 2015, Bioinform..

[31]  V. Pankratz,et al.  Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease , 2015, Neurobiology of Aging.

[32]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[33]  P. Crane,et al.  Alzheimer’s Disease: Analyzing the Missing Heritability , 2013, PloS one.

[34]  C. Jack,et al.  Ecology of the aging human brain. , 2011, Archives of neurology.

[35]  I. Driscoll,et al.  Asymptomatic Alzheimer's disease: a prodrome or a state of resilience? , 2011, Current Alzheimer research.

[36]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[37]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.